Medline reviews for Deprenyl

• Mov Disord 1993;8 Suppl 1:S8-13: Youdim MB; Riederer P
  The relevance of glial monoamine oxidase-B and polyamines to the action of selegiline in Parkinson's disease.
  
• Mov Disord 1993;8 Suppl 1:S31-5: Rinne JO
  Nigral degeneration in Parkinson's disease.
  
• Mov Disord 1993;8 Suppl 1:S20-30: Tatton WG
  Selegiline can mediate neuronal rescue rather than neuronal protection.
  
• Mov Disord 1993;8 Suppl 1:S1-7: Olanow CW
  A rationale for monoamine oxidase inhibition as neuroprotective therapy for Parkinson's disease.
  
• J Neurochem 1993 Oct;61(4):1191-206: Tipton KF; Singer TP
  Advances in our understanding of the mechanisms of the neurotoxicity of MPTP and related compounds.
  
• J Neural Transm Suppl 1993;40:93-9: Stern G
  Die Pathoklise [Parkinson's disease]
  
• J Neural Transm Suppl 1993;40:69-91: Knoll J
  The pharmacological basis of the beneficial effects of (-)deprenyl (selegiline) in Parkinson's and Alzheimer's diseases.
  
• J Neural Transm Suppl 1993;40:37-45: Glover V; Clow A; Sandler M
  Effects of dopaminergic drugs on superoxide dismutase: implications for senescence.
  
• Geriatrics 1993 Feb;48(2):30-4, 39-40: Paulson GW
  Management of the patient with newly-diagnosed Parkinson's disease.
  
• West J Med 1994 Sep;161(3):303-8: Aminoff MJ
  Treatment of Parkinson's disease.
  
• Neurochem Res 1993 Dec;18(12):1211-9: Milgram NW; Ivy GO; Head E; Murphy MP; Wu PH; Ruehl WW; Yu PH; Durden DA; Davis BA; Paterson IA; et al
  The effect of L-deprenyl on behavior, cognitive function, and biogenic amines in the dog.
  
• Neurochem Res 1993 Sep;18(9):1015-22: Paetsch PR; Greenshaw AJ
  2-Phenylethylamine-induced changes in catecholamine receptor density: implications for antidepressant drug action.
  
• Neurology 1994 Jul;44(7 Suppl 6):S19-22: Calne DB
  Initiating treatment for idiopathic parkinsonism.
  
• Cleve Clin J Med 1993 Jul-Aug;60(4):269-70: Sweeney PJ
  Parkinson's disease: where do we stand?
  
• Eur Neurol 1993;33 Suppl 1:24-30: Le Witt PA
  Neuroprotection by anti-oxidant strategies in Parkinson's disease.
  
• Med Clin North Am 1994 Jul;78(4):911-34: Schneider LS; Tariot PN
  Emerging drugs for Alzheimer's disease. Mechanisms of action and prospects for cognitive enhancing medications.
  
• Semin Vet Med Surg (Small Anim) 1994 Aug;9(3):127-31: Peterson ME; Kintzer PP
  Medical treatment of pituitary-dependent hyperadrenocorticism in dogs.
  
• Postgrad Med 1994 Apr;95(5):52-4, 57-8, 61-4 passim: Ahlskog JE
  Treatment of Parkinson's disease. From theory to practice.
  
• Ann N Y Acad Sci 1994 Jun 30;717:60-71: Kitani K; Kanai S; Carrillo MC; Ivy GO
  (-)Deprenyl increases the life span as well as activities of superoxide dismutase and catalase but not of glutathione peroxidase in selective brain regions in Fischer rats.
  
• Ann N Y Acad Sci 1994 Jun 30;717:45-59: Ivy GO; Rick JT; Murphy MP; Head E; Reid C; Milgram NW
  Effects of L-deprenyl on manifestations of aging in the rat and dog.
  
• J Neural Transm Gen Sect 1993;91(2-3):161-80: Olanow CW
  A scientific rationale for protective therapy in Parkinson's disease.
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):781-96: Tipton KF
  What is it that l-deprenyl (selegiline) might do?
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):750-6: Schneider LS; Tariot PN; Goldstein B
  Therapy with l-deprenyl (selegiline) and relation to abuse liability.
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):742-9: Heinonen EH; Anttila MI; Lammintausta RA
  Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites.
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):734-41: Lange KW; Riederer P; Youdim MB
  Biochemical actions of l-deprenyl (selegiline).
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):725-33: Youdim MB; Finberg JP
  Pharmacological actions of l-deprenyl (selegiline) and other selective monoamine oxidase B inhibitors.
  
• Clin Pharmacol Ther 1994 Dec;56(6 Pt 2):721-4: Goldberg SR; Yasar S; Bergman J; Youdim MB
  Introduction: examination of clinical and preclinical pharmacologic data relating to abuse liability of l-deprenyl (selegiline).
  
• Adv Neurol 1993;60:666-71: Olanow CW
  MAO-B inhibitors in Parkinson's disease.
  
• Med Clin North Am 1993 Jan;77(1):169-83: Standaert DG; Stern MB
  Update on the management of Parkinson's disease.
  
• Pediatr Neurol 1994 Mar;10(2):131-40: Pranzatelli MR; Mott SH; Pavlakis SG; Conry JA; Tate ED
  Clinical spectrum of secondary parkinsonism in childhood: a reversible disorder.
  
• Neurol Clin 1994 Aug;12(3):497-508: Golbe LI
  Pregnancy and movement disorders.
  
• J Am Geriatr Soc 1993 Nov;41(11):1219-25: Burke WJ; Roccaforte WH; Wengel SP; Bayer BL; Ranno AE; Willcockson NK
  L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.
  
• Int Clin Psychopharmacol 1993 Jan;7(3-4):167-80: Dingemanse J
  An update of recent moclobemide interaction data.
  
• Nippon Naika Gakkai Zasshi 1994 Mar 10;83(3):427-30: Yoshida M
  [Parkinson's disease--current topics]
  
• Curr Opin Neurol Neurosurg 1993 Jun;6(3):339-43: Lieberman A
  Treatment of Parkinson's disease.
  
• Life Sci 1994;55(25-26):2155-63: Stoll S; Hafner U; Pohl O; Muller WE
  Age-related memory decline and longevity under treatment with selegiline.
  
• J Neural Transm Suppl 1994;41:57-67: Kopin IJ
  Monoamine oxidase and catecholamine metabolism.
  
• J Neural Transm Suppl 1994;41:397-406: Yu PH; Davis BA; Boulton AA; Zuo DM
  Deamination of aliphatic amines by type B monoamine oxidase and semicarbazide-sensitive amine oxidase; pharmacological implications.
  
• J Neural Transm Suppl 1994;41:259-66: Delumeau JC; Bentue-Ferrer D; Gandon JM; Amrein R; Belliard S; Allain H
  Monoamine oxidase inhibitors, cognitive functions and neurodegenerative diseases.
  
• J Neural Transm Suppl 1994;41:207-19: Sziraki I; Kardos V; Patthy M; Patfalusi M; Gaal J; Solti M; Kollar E; Singer J
  Amphetamine-metabolites of deprenyl involved in protection against neurotoxicity induced by MPTP and 2'-methyl-MPTP.
  
• J Neural Transm Suppl 1994;41:177-88: Gerlach M; Youdim MB; Riederer P
  Is selegiline neuroprotective in Parkinson's disease?
  
• J Neural Transm Suppl 1994;41:167-75: Magyar K
  Behaviour of (-)-deprenyl and its analogues.
  
• Neuropsychopharmacology 1993 Aug;9(1):1-12: Kopin IJ
  Parkinson's disease: past, present, and future.
  
• Int J Neurosci 1993 May;70(1-2):75-84: Richardson JS
  On the functions of monoamine oxidase, the emotions, and adaptation to stress.
  
• Acta Neurol Scand Suppl 1993;146:50-3: Rinne UK
  Strategies in the treatment of early Parkinson's disease.
  
• Can J Neurol Sci 1992 Feb;19(1 Suppl):142-6: Vezina P; Mohr E; Grimes D
  Deprenyl in Parkinson's disease: mechanisms, neuroprotective effect, indications and adverse effects.
  
• Can J Neurol Sci 1992 Feb;19(1 Suppl):124-33: Tatton WG; Greenwood CE; Seniuk NA; Salo PT
  Interactions between MPTP-induced and age-related neuronal death in a murine model of Parkinson's disease.
  
• Can J Neurol Sci 1992 Feb;19(1 Suppl):113-6: Stoessl AJ
  Prevention and management of late stage complications in Parkinson's disease.
  
• Neurology 1992 Apr;42(4 Suppl 4):8-12; discussion 41-8: Goldstein M; Lieberman A
  The role of the regulatory enzymes of catecholamine synthesis in Parkinson's disease [see comments]
  
• Acta Pharm Hung 1992 Sep;62(5):259-64: Kovacs A
  ["Widening horizons" in the clinical application of selegiline]
  
• Acta Pharm Hung 1992 Sep;62(5):243-8: Szatmari I; Toth K
  [Pharmacokinetics and metabolism of selegiline]
  
• Acta Pharm Hung 1992 Sep;62(5):189-99: Hermecz I; Ecseryne Puskas M
  [A drug ahead of its time: the success story of selegiline]
  
• Ann Neurol 1992;32 Suppl:S143-5: Shoulson I
  Neuroprotective clinical strategies for Parkinson's disease.
  
• Acta Neurol Scand Suppl 1991;136:44-59: Heinonen EH; Lammintausta R
  A review of the pharmacology of selegiline.
  
• Eur J Pharmacol 1992 Jun 5;226(2):97-108: Gerlach M; Riederer P; Youdim MB
  The molecular pharmacology of L-deprenyl.
  
• No To Shinkei 1991 Aug;43(8):743-52: Ogawa N
  [New anti-parkinsonian drugs]
  
• Prog Drug Res 1992;38:171-297: Cesura AM; Pletscher A
  The new generation of monoamine oxidase inhibitors.
  
• Psychopharmacol Bull 1992;28(1):45-57: Rudorfer MV
  Monoamine oxidase inhibitors: reversible and irreversible.
  
• Neurology 1992 Apr;42(4 Suppl 4):13-26; discussion 41-8: Olanow CW; Calne D
  Does selegiline monotherapy in Parkinson's disease act by symptomatic or protective mechanisms?
  
• Prog Neuropsychopharmacol Biol Psychiatry 1991;15(2):139-56: Boulton AA
  Phenylethylaminergic modulation of catecholaminergic neurotransmission.
  
• Neurology 1992 Jan;42(1 Suppl 1):33-8; discussion 57-60: Koller WC
  Initiating treatment of Parkinson's disease.
  
• Acta Histochem Suppl 1992;42:25-31: Madeja UD
  [The dopamine agonist, lisuride, in the therapy of Parkinson disease]
  
• Drugs Aging 1991 May;1(3):228-48: Chrisp P; Mammen GJ; Sorkin EM
  Selegiline. A review of its pharmacology, symptomatic benefits and protective potential in Parkinson's disease.
  
• Med Res Rev 1992 Sep;12(5):505-24: Knoll J
  Pharmacological basis of the therapeutic effect of (-)deprenyl in age-related neurological diseases.
  
• Therapie 1992 Jan-Feb;47(1):75-8: Vermersch P; Petit H
  [Long-term selegiline tolerance in the treatment of Parkinson's disease]
  
• Ned Tijdschr Geneeskd 1992 Aug 8;136(32):1544-7: Wolters EC; Kuiper MA; Horstink MW
  [Selegiline in Parkinson's disease; symptomatic or causal effect? (published errata appear in Ned Tijdschr Geneeskd 1992 Aug 22; 136(34):1688 and 1992 Sep 5; 136(36):1792 and 1992 Dec 26; 136(52):2600)]
  
• Psychopharmacol Bull 1991;27(4):493-502: Mallinger AG; Smith E
  Pharmacokinetics of monoamine oxidase inhibitors.
  
• Therapie 1991 Jul-Aug;46(4):293-303: Montastruc JL
  Recent advances in the clinical pharmacology of Parkinson's disease.
  
• Acta Neurol Scand Suppl 1991;136:95-8: Rinne UK
  New strategies in the treatment of early Parkinson's disease.
  
• Acta Neurol Scand Suppl 1991;136:91-4: Lees AJ
  Selegiline hydrochloride and cognition.
  
• Acta Neurol Scand Suppl 1991;136:87-90: Rinne JO
  Nigral degeneration in Parkinson's disease in relation to clinical features.
  
• Acta Neurol Scand Suppl 1991;136:60-5: Oreland L
  Monoamine oxidase, dopamine and Parkinson's disease.
  
• Acta Neurol Scand Suppl 1991;136:37-9: Aquilonius SM
  What has PET told us about Parkinson's disease?
  
• Can J Neurol Sci 1991 Feb;18(1):85-6: Grimes JD
  Deprenyl: the exciting possibility of protective effect.
  
• Can J Neurol Sci 1991 Feb;18(1):83-5: Kofman OS
  Deprenyl: protective vs. symptomatic effect.
  
• Tidsskr Nor Laegeforen 1992 Oct 10;112(24):3106-9: Dietrichs E
  [Drug therapy of Parkinson disease]
  
• Geriatrics 1992 Jan;47(1):24-9: Pleet AB
  Newly-diagnosed Parkinson's disease: a therapeutic update.
  
• Ann N Y Acad Sci 1992 May 11;648:37-41: Shoulson I
  Antioxidative therapeutic strategies for Parkinson's disease.
  
• Drugs Aging 1992 Mar-Apr;2(2):112-24: Coleman RJ
  Current drug therapy for Parkinson's disease. A review.
  
• Eur Neurol 1992;32 Suppl 1:30-5: Olanow CW
  Early therapy for Parkinson's disease.
  
• Psychopharmacol Bull 1992;28(1):71-9: Schneider LS; Sobin PB
  Non-neuroleptic treatment of behavioral symptoms and agitation in Alzheimer's disease and other dementia.
  
• Neurol Clin 1992 May;10(2):553-65: Lieberman A
  An integrated approach to patient management in Parkinson's disease.
  
• Am J Med Sci 1991 Dec;302(6):392-5: Robin DW
  Selegiline in the treatment of Parkinson's disease.
  
• J Am Geriatr Soc 1992 Aug;40(8):839-47: Knoll J
  (-)Deprenyl-medication: a strategy to modulate the age-related decline of the striatal dopaminergic system.
  
• J Am Geriatr Soc 1991 Jul;39(7):708-16: Cummings JL
  Behavioral complications of drug treatment of Parkinson's disease.
  
• Lancet 1991 Jun 1;337(8753):1324-7: Clough CG
  Parkinson's disease: management.
  
• Pharmacol Toxicol 1992 May;70(5 Pt 1):317-21: Knoll J
  The pharmacological profile of (-)deprenyl (selegiline) and its relevance for humans: a personal view.
  
• Vojnosanit Pregl 1992 Jul-Aug;49(4):357-68: Stojiljkovic MP; Dragojevic-Simic V; Boskovic B
  [Selegiline in the therapy of Parkinson's disease]
  
• Prog Brain Res 1992;94:309-15: Yu PH; Davis BA; Boulton AA
  Neuronal and astroglial monoamine oxidase: pharmacological implications of specific MAO-B inhibitors.
  
• Clin Investig 1992 May;70(5):459-62: Wessel K; Szelenyi I
  Selegiline--an overview of its role in the treatment of Parkinson's disease.
  
• Arch Neurobiol (Madr) 1991 Nov-Dec;54(6):282-7: Rinne UK
  [Optimization of the treatment of Parkinson's disease using dopamine agonists (see comments)]
  
• Arch Neurobiol (Madr) 1991 Nov-Dec;54(6):277-81: Shoulson I
  [Therapeutic strategies in Parkinson's disease (see comments)]
  
• J Neural Transm Suppl 1992;38:27-44: Lange KW; Youdim MB; Riederer P
  Neurotoxicity and neuroprotection in Parkinson's disease.
  
• J Neural Transm Suppl 1992;38:129-40: Ransmayr G; Kunig G; Gerstenbrand F
  Modern therapy of Parkinson's disease.
  
• Can J Neurol Sci 1992 Feb;19(1 Suppl):156-9: King DB
  The place of the dopaminergic agonists in the treatment of Parkinson's disease: the view from the trenches.
  
• DICP 1991 Jan;25(1):36-40: Fuller MA; Tolbert SR
  Selegiline: initial or adjunctive therapy of Parkinson's disease?
  
• Ann Pharmacother 1992 Feb;26(2):227-33: Collier DS; Berg MJ; Fincham RW
  Parkinsonism treatment: Part III--Update.
  
• Neurol Clin 1992 May;10(2):541-52: Tetrud JW; Langston JW
  Protective and preventive therapeutic strategies: monoamine oxidase inhibitors.
  
• Neurol Clin 1992 May;10(2):511-26: Le Witt PA
  Treatment strategies for extension of levodopa effect.
  
• Rev Med Brux 1992 Dec;13(10):360-6: Przedborski S; Levivier M
  [Current therapeutic approach in Parkinson disease]
  
• Compr Ther 1992 Sep;18(9):20-4: Siemers E
  Recent progress in the treatment of Parkinson's disease.
  
• Acta Neurol Scand Suppl 1989;126:63-6: Birkmayer W; Birkmayer GJ
  Strategy and tactic of modern Parkinson therapy.
  
• Pharmacol Toxicol 1990 Aug;67(2):95-100: Kaakkola S; Teravainen H
  Animal models of parkinsonism.
  
• J Neural Transm Suppl 1989;28:53-63: Norman TR; Burrows GD
  Monoamine oxidase, monoamine oxidase inhibitors, and panic disorder.
  
• Prog Neuropsychopharmacol Biol Psychiatry 1989;13(3-4):395-403: Baker GB; Coutts RT
  Metabolism of monoamine oxidase inhibitors.
  
• Drugs 1990 May;39(5):646-51: Golbe LI; Langston JW; Shoulson I
  Selegiline and Parkinson's disease. Protective and symptomatic considerations.
  
• Neurology 1990 Oct;40(10 Suppl 3):suppl 61-6; discussion 67-9: Langston JW
  Selegiline as neuroprotective therapy in Parkinson's disease: concepts and controversies.
  
• Neurology 1990 Oct;40(10 Suppl 3):suppl 58-60: Koller WC; Giron LT Jr
  Selegiline HC1: Selective MAO-type B inhibitor.
  
• Adv Neurol 1990;53:425-9: Knoll J
  Nigrostriatal dopaminergic activity, deprenyl treatment, and longevity.
  
• Harefuah 1990 Dec 16;119(12):445-6: Susel Z; Yarnitsky D
  [Protective therapy in Parkinson's disease]
  
• Drug Metabol Drug Interact 1990;8(3-4):247-312: Lewis AJ; Kerenyi NA; Feuer G
  Neuropharmacology of pineal secretions.
  
• J Neural Transm Suppl 1990;32:239-48: Youdim MB; Ben-Shachar D; Riederer P
  The role of monoamine oxidase, iron-melanin interaction, and intracellular calcium in Parkinson's disease.
  
• Nervenarzt 1990 Feb;61(2):127-9: Baas H; Fischer PA
  [Slowing the progression of Parkinson syndrome by early administration of deprenyl]
  
• J Neurol Neurosurg Psychiatry 1990 Feb;53(2):93-5: Quinn N
  The modern management of Parkinson's disease.
  
• Drug Ther Bull 1989 Nov 27;27(24):95-6:
  Selegiline for parkinsonism--an update.
  
• Compr Ther 1990 Dec;16(12):41-6: Ahlskog JE
  Parkinson's disease: new treatment strategies.
  
• Neurol Clin 1990 Feb;8(1):31-49: Cedarbaum JM
  Pharmacokinetic and pharmacodynamic considerations in management of motor response fluctuations in Parkinson's disease.
  
• Prog Neuropsychopharmacol Biol Psychiatry 1988;12(2-3):165-72: Grimes JD; Hassan MN; Thakar JH
  Prevention of progression of Parkinson's disease with antioxidative therapy.
  
• Lancet 1990 Apr 21;335(8695):948-52: Marsden CD
  Parkinson's disease.
  
• J Neurol Neurosurg Psychiatry 1989 Jun;Suppl:29-37: Lees AJ
  The on-off phenomenon.
  
• Clin Neuropharmacol 1988 Oct;11(5):387-400: Golbe LI
  Deprenyl as symptomatic therapy in Parkinson's disease.
  
• R I Med J 1989 Nov;72(11):393-8: Friedman JH
  Parkinson's disease update.
  
• J Neural Transm Suppl 1990;29:259-68: Strolin Benedetti M; Cini M; Fusi R; Marrari P; Dostert P
  The effects of aging on MAO activity and amino acid levels in rat brain.
  
• Clin Neuropharmacol 1988 Dec;11(6):500-11: Sonsalla PK; Golbe LI
  Deprenyl as prophylaxis against Parkinson's disease?
  
• Br Med Bull 1990 Jan;46(1):124-46: Robertson DR; George CF
  Drug therapy for Parkinson's disease in the elderly.
  
• Acta Neurol Scand Suppl 1989;126:103-11: Heinonen EH; Rinne UK
  Selegiline in the treatment of Parkinson's disease.
  
• Ther Hung 1989;37(2):103-6: Bodo G; Elkan K; Bencze G
  Prevention of motion sickness with selegilinum hydrochloricum.
  
• Riv Neurol 1985 Jan-Feb;55(1):46-52: Amato L; Nava L; Rizzo M; Piccoli F
  [Biochemical basis for using selective monoamine oxidase inhibitors in the treatment of Parkinson's disease. Critical contribution]
  
• Conn Med 1985 Oct;49(10):633-7: Wirz D
  Update on the treatment of Parkinson's disease.
  
• Cell Biochem Funct 1986 Apr;4(2):99-108: Callingham BA
  Some aspects of monoamine oxidase pharmacology.
  
• Br J Psychiatry 1985 Jun;146:576-84: Pare CM
  The present status of monoamine oxidase inhibitors.
  
• Psychopharmacol Bull 1985;21(2):232-6: Rapoport JL; Zametkin A; Donnelly M; Ismond D
  New drug trials in attention deficit disorder.
  
• Union Med Can 1985 Dec;114(12):964-8, 973: Descarries L; Ferron A; Reader TA; de Montigny C
  [Interactions between monoaminergic neurons projecting to the cerebral cortex]
  
• Med J Aust 1987 Jun 15;146(12):634-8: Jarrott B; Vajda FJ
  The current status of monoamine oxidase and its inhibitors.
  
• J Neural Transm Suppl 1987;25:45-66: Knoll J
  R-(-)-deprenyl (Selegiline, Movergan) facilitates the activity of the nigrostriatal dopaminergic neuron.
  
• Mech Ageing Dev 1985 May 13;30(2):109-22: Knoll J
  The facilitation of dopaminergic activity in the aged brain by (-)deprenyl. A proposal for a strategy to improve the quality of life in senescence.
  
• Mov Disord 1986;1(3):159-62: Calne DB; Rinne UK
  Controversies in the management of Parkinson's disease.
  
• Experientia 1988 Feb 15;44(2):137-41: Youdim MB
  Platelet monoamine oxidase B: use and misuse.
  
• J Neural Transm Suppl 1986;22:91-105: Youdim MB
  Pharmacology of MAO B inhibitors: mode of action of (-)deprenyl in Parkinson's disease.
  
• J Neural Transm Suppl 1986;22:173-87: Giovannini P; Piccolo I; Scigliano G; Caraceni T
  Pharmacological approaches to Parkinson's disease in the different phases of evolution.
  
• J Neural Transm Suppl 1986;20:65-76: Glover V; Gibb C; Sandler M
  The role of MAO in MPTP toxicity--a review.
  
• J Neural Transm Suppl 1986;20:11-39: Jenner P; Marsden CD
  The actions of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine in animals as a model of Parkinson's disease.
  
• Clin Neuropharmacol 1986;9 Suppl 1:S37-54: Le Witt PA
  New perspectives in the treatment of Parkinson's disease.
  
• J Neural Transm Suppl 1987;25:5-12: Yahr MD
  R-(-)-deprenyl and parkinsonism.
  
• Eur Neurol 1987;27 Suppl 1:3-8: Dubuis R
  'On-off' phenomenon: description, incidence and management.
  
• J Neural Transm Suppl 1987;23:103-19: Strolin Benedetti M; Dostert P
  Overview of the present state of MAO inhibitors.
  
• Experientia 1984 Nov 15;40(11):1165-72: Da Prada M; Keller HH; Pieri L; Kettler R; Haefely WE
  The pharmacology of Parkinson's disease: basic aspects and recent advances.
  
• Mod Probl Pharmacopsychiatry 1983;19:246-54: Oreland L; Arai Y; Stenstrom A; Fowler CJ
  Monoamine oxidase activity and localisation in the brain and the activity in relation to psychiatric disorders.
  
• Mod Probl Pharmacopsychiatry 1983;19:126-34: Mutschler E; Mohrke W
  Kinetics of MAO inhibitors.
  
• Neuropharmacology 1983 Mar;22(3 Spec No):441-6: Finberg JP; Youdim MB
  Selective MAO A and B inhibitors: their mechanism of action and pharmacology.
  
• Vopr Med Khim 1982 Mar-Apr;28(2):2-9: Gorkin VZ
  [Recent advances in studies on the specific inhibition and nature of monoamine oxidases (review)]
  
• Recenti Prog Med 1984 Oct;75(10):889-901: Colucci d'Amato C; Puccini A; Cristillo A; Vizioli R
  [Biochemical bases of Parkinson disease]
  
• J Pharm Pharmacol 1981 Jun;33(6):341-7: Fowler CJ; Oreland L; Callingham BA
  The acetylenic monoamine oxidase inhibitors clorgyline, deprenyl, pargyline and J-508: their properties and applications.
  
• Geriatrics 1982 Sep;37(9):81-4, 89-91: Weiner M
  Update on antiparkinsonian agents.
  
• Braz J Med Biol Res 1984;17(3-4):223-56: Lewinsohn R
  Mammalian monoamine-oxidizing enzymes, with special reference to benzylamine oxidase in human tissues.
  
• Drugs 1984 Sep;28(3):236-62: Quinn NP
  Anti-parkinsonian drugs today.
  
• Isr J Psychiatry Relat Sci 1983;20(3):254-71: Zemishlany Z; Radwan M; Wijsenbeek H
  Monoamine oxidase inhibitors--current status.
  
• J Neural Transm Suppl 1980;(16):157-61: Youdim MB
  Monoamine oxidase inhibitors as anti-depressant drugs and as adjunct to L-dopa therapy of Parkinson's disease.
  
• Acta Neurol Scand Suppl 1978;67:77-113: Rinne UK
  Recent advances in research on Parkinsonism.
  
• Neurol Neurochir Pol 1980;14(2):209-12: Zaleska B
  [Progress in the treatment of degenerative diseases of the nervous system. Selected problems]
  
• Seikagaku 1980;52(3):158-62: Suzuki O
  [Current status of type A and type B monoamine oxidase (author's transl)]